CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 200 target
Drug / intervention
Core Needle, Forceps, or Punch Biopsyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05478538
NCT05478538N/AActiveOn Track
CompareCT.gov

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

Elephas·observational·Posted Jul 28, 2022·Updated Jun 29, 2026

In Brief

An observational study evaluating Core Needle, Forceps, or Punch Biopsy for NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 200 participants across 7 sites.

Detailed Summary

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

N/AActive
20232024202520262027
First PostedJul 28, 2022
Enrollment StartJan 31, 2023
Primary CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 3.9 years agoPrimary completion in 5 months

Interventions

Core Needle, Forceps, or Punch Biopsyprocedure

Subjects must be clinically able, at investigator discretion, to undergo additional core needle, forceps, or punch biopsy during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.